Abstract
Modern drug delivery systems rely on either antibody-based single-surface recognition or on surface-hydrophobicity-based approaches. For a tumor showing various surface mutations, both approaches fail. This publication hereby presents Janus capsules based on polyelectrolyte multilayer microcapsules exhibiting human leucocyte (THP-1 cell line) cell membranes for discriminating HUVEC cells from three different cancer cell lines. Despite destroying the cellular integrity of leucocyte cells, the modified Janus capsules are able to adhere to cancer cells. Leucocyte cell-membrane-coated Janus capsules are phagocytosed with the cellular membrane part pointing to the cells.
| Original language | English |
|---|---|
| Pages (from-to) | 4407-4415 |
| Number of pages | 9 |
| Journal | ACS Applied Materials and Interfaces |
| Volume | 8 |
| Issue number | 7 |
| DOIs | |
| State | Published - 24 Feb 2016 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- Janus capsule
- biocompatible
- leukocyte cell
- phagocytosis
- target recognition
Fingerprint
Dive into the research topics of 'How Leucocyte Cell Membrane Modified Janus Microcapsules are Phagocytosed by Cancer Cells'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver